Back to User profile » Dr Sachio Fushida

Papers published by Dr Sachio Fushida:


Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients

Ohe Y, Fushida S, Yamaguchi T, Kinoshita J, Saito H, Okamoto K, Nakamura K, Tajima H, Ninomiya I, Ohta T

Cancer Management and Research 2020, 12:1303-1311

Published Date: 20 February 2020

Multidisciplinary therapy for scirrhous gastric cancer: a retrospective analysis and proposal of new treatment strategy

Fushida S, Kinoshita J, Oyama K, Fujimura T, Tsukada T, Yamaguchi T, Ninomiya I, Ohta T

Cancer Management and Research 2018, 10:3833-3839

Published Date: 24 September 2018

Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial–mesenchymal transition and acts synergistically with 5-fluorouracil

Kurata T, Fushida S, Kinoshita J, Oyama K, Yamaguchi T, Okazaki M, Miyashita T, Tajima H, Ninomiya I, Ohta T

Cancer Management and Research 2018, 10:2729-2742

Published Date: 15 August 2018

The effect of HIF-1α and PKM1 expression on acquisition of chemoresistance

Okazaki M, Fushida S, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Ninomiya I, Harada S, Ohta T

Cancer Management and Research 2018, 10:1865-1874

Published Date: 4 July 2018

Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial

Fushida S, Kinoshita J, Kaji M, Oyama K, Hirono Y, Tsukada T, Fujimura T, Ohta T

Drug Design, Development and Therapy 2016, 10:2353-2358

Published Date: 25 July 2016

A randomized multicenter Phase II study of perioperative tiotropium intervention in gastric cancer patients with chronic obstructive pulmonary disease

Fushida S, Oyama K, Kaji M, Hirono Y, Kinoshita J, Tsukada T, Nezuka H, Nakano T, Noto M, Nishijima K, Fujimura T, Ohta T

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2177-2183

Published Date: 12 October 2015

Randomized Phase II trial of paclitaxel plus valproic acid vs paclitaxel alone as second-line therapy for patients with advanced gastric cancer

Fushida S, Kaji M, Oyama K, Hirono Y, Nezuka H, Takeda T, Tsukada T, Fujimoto D, Ohyama S, Fujimura T, Ohta T

OncoTargets and Therapy 2015, 8:939-941

Published Date: 23 April 2015

VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody

Fushida S, Oyama K, Kinoshita J, Yagi Y, Okamoto K, Tajima H, Ninomiya I, Fujimura T, Ohta T

OncoTargets and Therapy 2013, 6:1445-1451

Published Date: 16 October 2013